Ibrutinib induces responses in aggressive lymphomas

Share :
Published: 13 Apr 2012
Views: 4819
Rating:
Save
Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

Preliminary results from clinical trials in a subtype of lymphoma show that for a number of patients whose disease was not cured by other treatments, the drug ibrutinib can provide significant anti-cancer responses with modest side effects.

 

Early results from the trial were presented at AACR 2012 in Chicago.

 

Click here for the offical press release